7254-34-4

Usage

Uses

3-Cyano-2-methoxypyridine is used as an organic chemical synthesis intermediate.

InChI:InChI=1/C7H6N2O/c1-10-7-6(5-8)3-2-4-9-7/h2-4H,1H3

Upstream product

• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 67-56-1 methanol 
• 75-05-8 acetonitrile 
• 163105-90-6 2-methoxypyridin-3-yl-boronic acid 
• 124-41-4 sodium methylate 
• 18356-02-0 methyl sodium 
• 52505-45-0 2-mercaptopyridine-3-carbonitrile 
• 145325-29-7 2-allylsuphanyl-3-cyanopyridine 

Downstream Products

• 7145-28-0 2-methoxy-3-pyridinecarboxamide 
• 1346870-63-0 1-benzyl-3-cyano-4-phenyl-2-oxo-1,2-dihydropyridine 
• 1346870-65-2 1,4-dibenzyl-3-cyano-2-oxo-1,2-dihydropyridine 
• 1346870-69-6 1-benzyl-3-cyano-4-(2-methylphenyl)-2-oxo-1,2-dihydropyridine 
• 1346870-70-9 1-benzyl-3-cyano-4-(4-methylphenyl)-2-oxo-1,2-dihydropyridine 
• 1346870-72-1 1-benzyl-3-cyano-4-(2-methoxyphenyl)-2-oxo-1,2-dihydropyridine 
• 1346870-73-2 1-benzyl-3-cyano-4-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine 
• 74124-17-7 1-benzyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 1446002-31-8 5-iodo-2-methoxy-nicotinonitrile 
• 1392150-47-8 5-(3,5-difluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 941294-54-8 5-bromo-2-methoxypyridine-3-carbonitrile 

Relevant academic research and scientific papers

Uses for whitening material of 4-(4-methylpiperazin-1-yl)-N-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)benzamide derivatives, or pharmaceutical acceptable salt thereof

The present invention relates to uses for a whitening material of a 4-(4-methylpiperazin-1-yl)-N-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)benzamide derivative, or a pharmaceutically acceptable salt thereof. A composition for whitening provided in

Novel 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase)

The present invention relates to a 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivative or pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating maternal embryonic leu

Cu-Catalyzed Cyanation of Arylboronic Acids with Acetonitrile: A Dual Role of TEMPO

The cyanation of arylboronic acids by using acetonitrile as the "CN" source has been achieved under a Cu(cat.)/TEMPO system (TEMPO=2,2,6,6-tetramethylpiperidine N-oxide). The broad substrate scope includes a variety of electron-rich and electron-poor arylboronic acids, which react well to give the cyanated products in high to excellent yields. Mechanistic studies reveal that TEMPO-CH2CN, generated in situ, is an active cyanating reagent, and shows high reactivity for the formation of the CN- moiety. Moreover, TEMPO acts as a cheap oxidant to enable the reaction to be catalytic in copper. The cyanation of arylboronic acids by using acetonitrile as the "CN" source has been achieved under a Cu(cat.)/TEMPO system. Electron-rich and electron-poor arylboronic acids react well to give the cyanated products in high to excellent yields. Mechanistic studies reveal that TEMPO-CH2CN, generated in situ, is an active cyanating reagent. Moreover, TEMPO, a cheap oxidant, enables the reaction to be catalytic in copper (see scheme; TEMPO=2,2,6,6-tetramethylpiperidine N-oxide).

Derivatives of azaindoles or diazaindoles for treating pain

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

Trideuteriomethoxylation of aryl and heteroaryl halides

Direct access to trideuteriomethoxylated aromatic and heteroaromatic compounds has been developed. Various aryl and heteroaryl halides underwent d3-methoxylation under mild reaction conditions by using a catalyst system composed of the commercially available monodentate phosphane ligand tBuXPhos and Pd(OAc)2. Inexpensive CD3OD served as an efficient trideuteriomethoxylating agent. The simple and straightforward synthesis of labeled methyl (hetero)aryl ethers via palladium-catalyzed C-O cross-coupling reaction of (hetero)aryl halides with CD3OD was developed. The tBuXPhos ligand is used for the first time in ether synthesis. Copyright